Journals Guilty of Citation Inflation

A record 66 journals have been banned from this year’s impact-factor list for citation foulplay.

Written byChris Palmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, MIKE FERNWOODWith the release of the 2013 Thomson Reuters journal impact factor list comes news that a record number of journals have been excluded from the list for attempting to rig their ratings. This year, 66 journals—including 37 first time offenders—will not be included on the annual list, which measures the average number of times papers from individual journals are cited. Reasons for exclusion include excessive self-citation and “citation stacking”—a ploy in which journals cite each other to an excessive degree. Thomson Reuters, the publishing giant that publishes the list, claims the self-citations distort rankings. The company says that banned excluded journals will be reconsidered for inclusion after 2 years.

The number of banned journals is a tiny fraction—0.5 percent—of the 10,853 journals that received a ranking, including 379 journals that are receiving their first impact factor. And while some journals jockey for position on the citation rankings, others have downplayed the importance of the impact factor. This May saw release of the San Francisco Declaration on Research Assessment (DORA) by a group of scientific editors and publishers declaring that impact factor is not an adequate measure to judge the worthiness of individual journals, nor the careers of individual scientists.

Biologist George Lozano, who recently performed an analysis of citations in 29 million papers over the past century, poked holes in the usefulness of the impact factor in his June 8 blog post for the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies